Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and …
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $1.25 | $1.17 | $1.12 |
| Estimado | $1.18 | $1.28 | $1.21 | $1.30 |
| Sorpresa | — | -2.3% | -3.3% | -13.8% |
| Métrica | DIM.PA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 45.3% | 57.4% | -12.1% |
| Operating Margin | 17.7% | -34.4% | +52.1% |
| Net Margin | 8.9% | -32.5% | +41.4% |
| FCF Margin | — | -12.6% | — |
| ROE | 6.5% | -39.2% | +45.7% |
| ROA | 3.3% | -30.9% | +34.3% |
| Current Ratio | 1.02 | 2.73 | -1.71 |
| Debt / Equity | 0.46 | 0.28 | +0.18 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 3.3% | — |
| ✓Flujo de caja operativo positivo | €692M | €815M |
| ✓Rentabilidad sobre activos al alza | 3.3% | 2.1% |
| ✓Caja operativa/activos supera al ROA | 8.7% | ROA 3.3% |
| ✓Menos deuda a largo plazo | 23.4% | 32.5% |
| ✗Mejor liquidez (ratio corriente) | 1.02 | 1.85 |
| ✗Sin aumentar el nº de acciones | 97M | 97M |
| ✓Margen bruto al alza | 45.3% | 43.4% |
| ✓Rotación de activos al alza | 0.37 | 0.34 |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | 8.0% |
| ✗Ventas > 5 %/año (3 años) | -5.3% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 4.5% |
Sartorius Stedim Biotech cotiza a 215.00 EUR y tiene una capitalización bursátil de €20.9B. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud